A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

计划入组 9 人 · 首次发布于 2026 年 6 月 30 日

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

计划入组 9 人 · 首次发布于 2026 年 7 月 23 日

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

计划入组 1,560 人 · 首次发布于 2025 年 3 月 24 日

mRNA vaccine

mRNA RSV vaccine

mRNA-1893

AIM VACCINE

China

Finlay Vaccine Institute

Path Vaccine Solutions

United States

CEPI Awards $5 Million to Nagasaki University for Revolutionary 'Nanoball' mRNA Vaccine Platform

CEPI Awards $5 Million to Nagasaki University for AI-Powered Nanoball mRNA Vaccine Platform Against Disease X

FDA Approves Moderna's mRNA Influenza Vaccine